ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis.
Kumar
M S
MS
Division of Transplantation, Allegheny Hahnemann University Hospitals, Philadelphia, Pennsylvania 19102, USA.
Cahill
K
K
Kumar
A M
AM
Panigrahi
D
D
Seirka
D
D
Singleton
R
R
al-Abdullah
I H
IH
Laskow
D A
DA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D017252:CD3 Complex; D002648:Child; D003141:Communicable Diseases / Q000453:epidemiology; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology; D011446:Prospective Studies; D015996:Survival Rate; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D016559:Tacrolimus / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D017252:CD3 Complex; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D009173:Mycophenolic Acid; D016559:Tacrolimus